Piper Sandler analyst Allison Bratzel raised the firm’s price target on Argenx to $600 from $595 and keeps an Overweight rating on the shares. The analyst increased near-term Vyvgart estimates following a 149 neurologist survey, which the firm views as bullish. The shift toward earlier-line Vyvgart adoption is well underway, and projected uptake of the Vyvgart Hytrulo format is “impressive” and indicates less cannibalization of IV Vyvgart than expected, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARGX:
- argenx to Present at Upcoming Investor Conferences
- Argenx price target raised to EUR 500 from EUR 425 at Deutsche Bank
- Adobe upgraded, Salesforce downgraded: Wall Street’s top analyst calls
- Argenx initiated with a Sector Perform at Scotiabank
- Argenx price target raised to $590 from $545 at Guggenheim